UTHR Trading Analysis - 10/15/2026 05:20 PM — TRU-SENTIMENT

News Headlines & Context

United Therapeutics (UTHR) is a biotechnology firm focused on therapies for pulmonary arterial hypertension and rare diseases. Based on general knowledge (not embedded data), recent context includes:

• UTHR received FDA approval expansion for Tyvaso in earlier-stage PAH, potentially widening addressable market.
• Company presented positive long-term survival data for treprostinil-based regimens at a major cardiology conference.
• Patent litigation over generic treprostinil remains ongoing, creating overhang risk for future revenue.
• No near-term earnings date confirmed in provided data, but fiscal year end per fundamentals is 2025-12-01.
• Headlines suggest fundamental strength, which contrasts with the bearish options sentiment seen in embedded data — a possible divergence where news is constructive but short-term positioning is defensive.

Fundamental Analysis

From the provided FUNDAMENTALS data (sourced locally, no external links):

• Trailing P/E: 17.90; Trailing EPS: 30.28 — valuation appears modest vs. biotech peers, though PEG ratio is null (not available).
• Market Cap: 23,225,905,410.00; Shares Outstanding: 42,891,000.00; Institutional Ownership: 57.01%.
• Dividend Yield: 0.00%; no dividend declared (ex-dividend date null).
• Beta: 0.14 — very low market correlation, suggesting defensive profile.
• 52-Week Range: 409.07 to 609.35; current price 542.10 sits mid-range.
• Revenue growth, gross/operating/net margins, ROE, debt/equity, and free cash flow are null in data — cannot assess trend quality.
• Forward P/E, target mean price, and analyst consensus are null — no street view provided.
• Fundamentals show low-beta, profitable (EPS 30.28), reasonable P/E 17.90, but lack of margin/data detail diverges from bullish technicals and bearish options flow.

Current Market Position

Current price per indicators: 542.10. Daily history shows 2026-10-15 close 542.10, intraday high 551.83, low 540.00, volume 317,088 (below 20-day avg 557,198). Minute bars (2026-10-14 to 2026-10-15) show open 543.18 dipping to 523.95 then recovering to 541.77–547.82 area; final 15:55 bar close 542.28 on volume 61,916. Intraday momentum flattened after mid-session weakness. Recent daily action: steep Sept 30 jump to 543.59 on 2.81M volume, then ranging 536–576 through Oct.

Technical Analysis

SMA alignment: 5 (545.50) > 20 (522.12) > 50 (514.99) — bullish stack, no bearish cross. RSI 67.27 near overbought but not extreme. MACD histogram positive 2.18 confirms bullish momentum. Price 542.10 above mid-band 522.12, below upper 583.77 — room to expand. 30-day range 468.97–585.79; price at ~55% of range. ATR 24.33 implies daily swing risk.

True Sentiment Analysis (Delta 40-60 Options)

Per True Sentiment Options (2026-10-15):

Call Volume: $255,740.00 (21.10%) Put Volume: $955,960.00 (78.90%) Total: $1,211,700.00

Sentiment: Bearish. Put dollar vol 3.7x calls; 316 put contracts vs 58 call. Pure directional conviction leans defensive. Divergence: technicals bullish, options bearish — spread recommender flagged "Wait for alignment".

Key Price Levels (Observational Only)